

(別添4)

研究成果の刊行に関する一覧表

- 1) Mizukami T, Shiraishi K, Shimada Y, Ogiwara H, Tsuta K, Ichikawa H, Sakamoto H, Kato M, Shibata T, Nakano T, Kohno T. Molecular mechanisms underlying oncogenic RET fusion in lung adenocarcinoma. *J Thoracic Oncol* 2014, 9 (5): 622-630
- 2) Nakaoku T, Tsuta K, Ichikawa H, Shiraishi K, Sakamoto H, Enari M, Furuta K, Shimada Y, Ogiwara H, Watanabe SI, Nokihara H, Yasuda K, Hiramoto M, Nammo T, Ishigame T, Schetter AJ, Okayama H, Harris CC, Kim YH, Mishima M, Yokota J, Yoshida T, Kohno T. Druggable Oncogene Fusions in Invasive Mucinous Lung Adenocarcinoma. *Clin Cancer Res* 2014, in press.
- 3) Romero OA, Torres-Diz M, Pros E, Savola S, Gomez A, Moran S, Saez C, Iwakawa R, Villanueva A, Montuenga LM, Kohno T, Yokota J, Sanchez-Cespedes M. MAX inactivation in small cell lung cancer disrupts MYC-SWI/SNF programs and is synthetic lethal with BRG1. *Cancer Discov* 2014;4:292-303.
- 4) Kohno T, Tsuta K, Tsuchihara K, Nakaoku T, Yoh K, Goto K. RET fusion gene: translation to personalized lung cancer therapy. *Cancer Sci* 2013;104:1396-400.
- 5) Oike T, Ogiwara H, Tominaga Y, Ito K, Ando O, Tsuta K, Mizukami T, Shimada Y, Isomura H, Komachi M, Furuta K, Watanabe S, Nakano T, Yokota J, Kohno T. A synthetic lethality-based strategy to treat cancers harboring a genetic deficiency in the chromatin remodeling factor BRG1. *Cancer Res* 2013;73:5508-18.
- 6) Akagi I, Okayama H, Schetter AJ, Robles AI, Kohno T, Bowman ED, Kazandjian D, Welsh JA, Oue N, Saito M, Miyashita M, Uchida E, Takizawa T, Takenoshita S, Skaug V, Mollerup S, Haugen A, Yokota J, Harris CC. Combination of protein coding and noncoding gene expression as a robust prognostic classifier in stage I lung adenocarcinoma. *Cancer Res* 2013;73:3821-32.
- 7) Iwakawa R, Takenaka M, Kohno T, Shimada Y, Totoki Y, Shibata T, Tsuta K, Nishikawa R, Noguchi M, Sato-Otsubo A, Ogawa S, Yokota J. Genome-wide identification of genes with amplification and/or fusion in small cell lung cancer. *Genes Chromosomes Cancer* 2013;52:802-16.
- 8) Yoshida A, Kohno T, Tsuta K, Wakai S, Shimada Y, Arai Y, Asamura H, Furuta K, Shibata T, Tsuda H. ROS1-Rearranged Lung Cancer: Clinicopathologic and Molecular Study of 15 Surgical Cases. *Am J Surg Pathol* 2013;37:554-62.
- 9) Otsubo C, Otomo R, Miyazaki M, Matsushima-Hibiya Y, Kohno T, Iwakawa R, Takeshita F, Okayama H, Ichikawa H, Saya H, Kiyono T, Ochiya T, Tashiro F, Nakagama H, Yokota J, Enari M. TSPAN2 Is Involved in Cell Invasion and Motility during Lung Cancer Progression. *Cell Rep* 2014 Apr 9. [Epub ahead of print]
- 10) Ogata-Kawata H, Izumiya M, Kurioka D, Honma Y, Yamada Y, Furuta K, Gunji T, Ohta H, Okamoto H, Sonoda H, Watanabe M, Nakagama H, Yokota J, Kohno T, Tsuchiya N. Circulating Exosomal microRNAs as Biomarkers of Colon Cancer. *PLoS One* 2014;9:e92921.
- 11) Ragin C, Obikoya-Malomo M, Kim S, Chen Z, Flores-Obando R, Gibbs D, Koriyama C, Aguayo F, Koshiol J, Caporaso NE, Carpagnano GE, Ciotti M, Dosaka-Akita H, Fukayama M, Goto A, Spandidos DA, Gorgoulis V, Heideman DA, van Boerdonk RA, Hiroshima K, Iwakawa R, Kastrinakis NG, Kinoshita I, Akiba S, Landi MT, Eugene Liu H, Wang JL, Mehra R, Khuri FR, Lim WT, Owonikoko TK, Ramalingam S, Sarchianaki E, Syrjanen K, Tsao MS, Sykes J, Hee SW, Yokota J, Zaravinos A, Taioli E. HPV-associated lung cancers: an international pooled analysis. *Carcinogenesis* 2014 Feb 26. [Epub ahead of print]
- 12) Murata Y, Minami Y, Iwakawa R, Yokota J, Usui S, Tsuta K, Shiraishi K, Sakashita S, Satomi K, Iijima T, Noguchi M. ECT2 amplification and overexpression as a new prognostic biomarker for early-stage lung adenocarcinoma. *Cancer Sci* 2014;105:490-7.
- 13) Oike T, Ogiwara H, Nakano T, Yokota J, Kohno T. Inactivating mutations in SWI/SNF chromatin remodeling genes in human cancer. *Jpn J Clin Oncol* 2013;43:849-55.
- 14) Ohata H, Miyazaki M, Otomo R, Matsushima-Hibiya Y, Otsubo C, Nagase T, Arakawa H, Yokota J, Nakagama H, Taya Y, Enari M. NuMA Is Required for the Selective Induction of p53-Target Genes. *Mol Cell Biol* 2013;33:2447-57.
- 15) Ui A, Ogiwara H, Nakajima S, Kanno S, Watanabe R, Harata M, Okayama H, Harris CC, Yokota J, Yasui A, Kohno T. Possible involvement of LKB1-AMPK signaling in non-homologous end joining.

Oncogene 2014;33:1640-8.

- 16) Akca H, Demiray A, Yaren A, Bir F, Koseler A, Iwakawa R, Bagci G, Yokota J. Utility of serum DNA and pyrosequencing for the detection of EGFR mutations in non-small cell lung cancer. *Cancer Genet* 2013;206:73-80.
- 17) Kohno T, Shiraishi K. Genetic polymorphisms underlying lung cancer susceptibility and therapeutic Response. *Genes and Environment*, 2012;34:94-100.
- 18) Kohno T, Ichikawa H, Totoki Y, Yasuda K, Hiramoto M, Nammo T, Sakamoto H, Tsuta K, Furuta K, Shimada Y, Iwakawa R, Ogiwara H, Oike T, Enari M, Schetter AJ, Okayama H, Haugen A, Skaug V, Chiku S, Yamanaka I, Arai Y, Watanabe S, Sekine I, Ogawa S, Harris CC, Tsuda H, Yoshida T, Yokota J, Shibata T. KIF5B-RET fusions in lung adenocarcinoma. *Nature Med* 2012;18:375-7.
- 19) Chen LS, Saccone NL, Culverhouse RC, Bracci PM, Chen CH, Dueker N, Han Y, Huang H, Jin G, Kohno T, Ma JZ, Przybeck TR, Sanders AR, Smith JA, Sung YJ, Wenzlaff AS, Wu C, Yoon D, Chen YT, Cheng YC, Cho YS, David SP, Duan J, Eaton CB, Furberg H, Goate AM, Gu D, Hansen HM, Hartz S, Hu Z, Kim YJ, Kittner SJ, Levinson DF, Mosley TH, Payne TJ, Rao DC, Rice JP, Rice TK, Schwantes-An TH, Shete SS, Shi J, Spitz MR, Sun YV, Tsai FJ, Wang JC, Wrensch MR, Xian H, Gejman PV, He J, Hunt SC, Kardia SL, Li MD, Lin D, Mitchell BD, Park T, Schwartz AG, Shen H, Wiencke JK, Wu JY, Yokota J, Amos CI, Bierut LJ. Smoking and genetic risk variation across populations of European, Asian, and African American ancestry--a meta-analysis of chromosome 15q25. *Genet Epidemiol* 2012;36:340-51.
- 20) Shiraishi K, Kunitoh H, Daigo Y, Takahashi A, Goto K, Sakamoto H, Ohnami S, Shimada Y, Ashikawa K, Saito A, Watanabe S, Tsuta K, Kamatani N, Yoshida T, Nakamura Y, Yokota J, Kubo M, Kohno T. A genome-wide association study identifies two new susceptibility loci for lung adenocarcinoma in the Japanese population. *Nat Genet* 2012;44:900-3.
- 21) Oike T, Ogiwara H, Torikai K, Nakano T, Yokota J, Kohno T. Garcinol, a histone acetyltransferase inhibitor, radiosensitizes cancer cells by inhibiting non-homologous end joining. *Int J Radiat Oncol Biol Phys* 2012;84:815-21.
- 22) Okayama H, Kohno T, Ishii Y, Shimada Y, Shiraishi K, Iwakawa R, Furuta K, Tsuta K, Shibata T, Yamamoto S, Watanabe S, Sakamoto H, Kumamoto K, Takenoshita S, Gotoh N, Mizuno H, Sarai A, Kawano S, Yamaguchi R, Miyano S, Yokota J. Identification of genes up-regulated in ALK-positive and EGFR/KRAS/ALK-negative lung adenocarcinomas. *Cancer Res* 2012;72:100-11.
- 23) Iwakawa R, Okayama H, Kohno T, Sato-Otsubo A, Ogawa S, Yokota J. Contribution of germline mutations to PARK2 gene inactivation in lung adenocarcinoma. *Genes, Chromosomes & Cancer* 2012;51:462-72.
- 24) Yamauchi M, Yamaguchi R, Nakata A, Kohno T, Nagasaki M, Shimamura T, Imoto S, Saito A, Ueno K, Hatanaka Y, Yoshida R, Higuchi T, Nomura M, Beer DG, Yokota J, Miyano S, Gotoh N. Epidermal growth factor receptor tyrosine kinase defines critical prognostic genes of stage I lung adenocarcinoma. *PLoS One* 2012;7:e43923.
- 25) Lan Q, Hsiung CA, Matsuo K, Hong YC, Seow A, Wang Z, Hosgood HD 3rd, Chen K, Wang JC, Chatterjee N, Hu W, Wong MP, Zheng W, Caporaso N, Park JY, Chen CJ, Kim YH, Kim YT, Landi MT, Shen H, Lawrence C, Burdett L, Yeager M, Yuenger J, Jacobs KB, Chang IS, Mitsudomi T, Kim HN, Chang GC, Bassig BA, Tucker M, Wei F, Yin Z, Wu C, An SJ, Qian B, Lee VH, Lu D, Liu J, Jeon HS, Hsiao CF, Sung JS, Kim JH, Gao YT, Tsai YH, Jung YJ, Guo H, Hu Z, Hutchinson A, Wang WC, Klein R, Chung CC, Oh IJ, Chen KY, Berndt SI, He X, Wu W, Chang J, Zhang XC, Huang MS, Zheng H, Wang J, Zhao X, Li Y, Choi JE, Su WC, Park KH, Sung SW, Shu XO, Chen YM, Liu L, Kang CH, Hu L, Chen CH, Pao W, Kim YC, Yang TY, Xu J, Guan P, Tan W, Su J, Wang CL, Li H, Sihoe AD, Zhao Z, Chen Y, Choi YY, Hung JY, Kim JS, Yoon HI, Cai Q, Lin CC, Park IK, Xu P, Dong J, Kim C, He Q, Perng RP, Kohno T, Kweon SS, Chen CY, Vermeulen R, Wu J, Lim WY, Chen KC, Chow WH, Ji BT, Chan JK, Chu M, Li YJ, Yokota J, Li J, Chen H, Xiang YB, Yu CJ, Kunitoh H, Wu G, Jin L, Lo YL, Shiraishi K, Chen YH, Lin HC, Wu T, Wu YL, Yang PC, Zhou B, Shin MH, Fraumeni JF. Jr, Lin D, Chanock SJ, Rothman N. Genome-wide association analysis identifies new lung cancer susceptibility loci in never-smoking women in Asia. *Nat Genet* 2012;44:1330-5.
- 26) Ogiwara H, Kohno T. Essential factors for incompatible DNA end joining at chromosomal DNA double strand breaks in vivo. *PLoS One* 2011;6:e28756.
- 27) Li S, Kanno S, Watanabe R, Ogiwara H, Kohno T, Watanabe G, Yasui A, Lieber MR. PALF acts as both a single-stranded DNA endonuclease and a single-stranded DNA 3' -exonuclease and can participate in DNA end joining in a biochemical system. *J Biol Chem* 2011;286:36368-77.

- 28) Yoshida A, Tsuta K, Nakamura H, Kohno T, Takahashi F, Asamura H, Sekine I, Fukayama M, Shibata T, Furuta K, Tsuda H. Comprehensive histological analysis of ALK-rearranged lung carcinomas. *Am J Surg Pathol* 2011;35:1226-34.
- 29) Yoshida A, Tsuta K, Nitta H, Hatanaka Y, Asamura H, Sekine I, Grogan TM, Fukayama M, Shibata T, Furuta K, Kohno T, Tsuda H. Bright-field dual color chromogenic insitu hybridization for diagnosing EML4-ALK-positive lung adenocarcinomas. *J Thoracic Oncol* 2011;6:1677-86.
- 30) Ogiwara H, Ui A, Otsuka A, Satoh H, Yokomi I, Nakajima S, Yasui A, Yokota J, Kohno T. Histone acetylation by CBP and p300 at double strand break sites facilitates SWI/SNF chromatin remodeling and the recruitment of non-homologous end joining factors. *Oncogene* 2011;30:2135-2146.
- 31) Iwakawa R, Kohno T, Kato M, Shiraishi K, Tsuta K, Noguchi M, Ogawa S, Yokota J. MYC amplification as a prognostic marker of early stage lung adenocarcinoma identified by whole genome copy number analysis. *Clin Cancer Res* 2011;17:1481-9.
- 32) Akca H, Demiray A, Tokgun O, Yokota J. Invasiveness and anchorage independent growth ability augmented by PTEN inactivation through PI3K/AKT/NFkB pathway in lung cancer cells. *Lung Cancer* 2011;73:302-9.
- 33) Saito M, Schetter AJ, Mollerup S, Kohno T, Skaug V, Bowman ED, Mathe E, Takenoshita S, Yokota J, Haugen A, Harris CC. The association of microRNA expression with prognosis and progression in early stage, non-small cell lung adenocarcinoma: a retrospective analysis of three cohorts. *Clin Cancer Res* 2011;17:1875-82.
- 34) Yamauchi M, Yoshino I, Yamaguchi R, Shimamura T, Nagasaki M, Imoto S, Niida A, Koizumi F, Kohno T, Yokota J, Miyano S, Goto N. N-cadherin expression is a potential survival mechanism of gefitinib-resistant lung cancer cells. *Am J Cancer Res* 2011;1:823-33.
- 35) Yano S, Yamada T, Takeuchi S, Tachibana K, Minami Y, Yatabe Y, Mitsudomi T, Tanaka H, Kimura T, Kudoh S, Nokihara H, Ohe Y, Yokota J, Uramoto H, Yasumoto K, Kiura K, Higashiyama M, Oda M, Saito H, Yoshida J, Kondoh K, Noguchi M. Hepatocyte growth factor expression in EGFR mutant lung cancer with intrinsic and acquired resistance to tyrosine kinase inhibitors in a Japanese cohort. *J Thorac Oncol* 2011;6:2011-7.
- 36) Kohno T, Kunitoh H, Mimaki S, Shiraishi K, Kuchiba A, Yamamoto S, Yokota J. Contribution of the TP53, OGG1, CHRNA3 and HLA-DQA1 genes to the risk for lung squamous cell carcinoma. *J Thoracic Oncol* 2011;6:813-7.
- 37) Kohno T, Otsuka A, Girard L, Sato M, Iwakawa R, Ogiwara H, Sanchez-Cespedes M, Minna JD, Yokota J. A catalog of genes homozygously deleted in human lung cancer and the candidacy of PTPRD as a tumor suppressor gene. *Genes Chromosomes Cancer* 2010;49:342-52.
- 38) Kodama M, Otsubo C, Hirota T, Yokota J, Enari M, Taya Y. Requirement of ATM for Rapid p53 Phosphorylation at Ser46 without Ser/Thr-Gln Sequences. *Mol Cell Biol* 2010;30:1620-33.
- 39) Kohno T, Kunitoh H, Shimada Y, Shiraishi K, Ishii Y, Goto K, Ohe Y, Nishiwaki Y, Kuchiba A, Yamamoto S, Hirose H, Oka A, Yanagitani N, Saito R, Inoko H, Yokota J. Individuals susceptible to lung adenocarcinoma defined by combined HLA-DQA1 and TERT genotypes. *Carcinogenesis* 2010;31:834-41.
- 40) Roy BC, Kohno T, Iwakawa R, Moriguchi T, Kiyono T, Morishita K, Sanchez-Cespedes M, Akiyama T, and Yokota J. Involvement of LKB1 in epithelial-mesenchymal transition of human lung cancer cells. *Lung Cancer* 2010;70:136-45.
- 41) Iwakawa R, Kohno T, Enari M, Kiyono T, Yokota J. Prevalence of human papilloma virus 16/18/33 infection and p53 mutation in lung adenocarcinoma. *Cancer Sci* 2010;101:1891-6.
- 42) Kohno T, Kakinuma R, Iwasaki M, Yamaji T, Kunitoh H, Suzuki K, Shimada Y, Shiraishi K, Kasuga Y, Hamada GS, Furuta K, Tsuta K, Sakamoto H, Kuchiba A, Yamamoto S, Kanai Y, Tsugane S, Yokota J. Association of CYP19A1 polymorphisms with risks for atypical adenomatous hyperplasia and bronchioloalveolar carcinoma in the lung. *Carcinogenesis* 2010;31:1794-9.
- 43) Shiraishi K, Kohno T, Tanai C, Goto Y, Kuchiba A, Yamamoto S, Tsuta K, Nokihara H, Yamamoto N, Sekine I, Ohe Y, Tamura T, Yokota J, Kunitoh H. Association of DNA repair gene polymorphisms with response to Platinum-based doublet chemotherapy in patients with non-small-cell lung cancer. *J Clin Oncol* 2010;28:4945-52.
- 44) Saito M, Kumamoto K, Robles AI, Horikawa I, Furusato B, Okamura S, Goto A, Yamashita T, Nagashima M, Lee T-L, Baxendale VJ, Rennert OM, Takenoshita S, Yokota J, Sesterhenn IA, Trivers GE, Hussain SP, Harris C C. Targeted disruption of ing2 results in defective

- spermatogenesis and development of soft-tissue sarcomas. *PLoS One* 2010;5:e15541.
- 45) Travis WD, Brambilla E, Noguchi M, Nicholson A, Geisinger K, Yatabe Y, Ishikawa Y, Wistuba I, Flieder DB, Franklin W, Gazdar A, Hasleton PS, Henderson DW, Kerr KM, Nakatani Y, Petersen I, Roggli V, Thunnissen E, Tsao M. Diagnosis of Lung Adenocarcinoma in Resected Specimens: Implications of the 2011 International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society Classification. *Arch Pathol Lab Med* 2013;137:685-705.
 - 46) Travis WD, Brambilla E, Noguchi M, Nicholson A, Geisinger K, Yatabe Y, Ishikawa Y, Wistuba I, Flieder DB, Franklin W, Gazdar A, Hasleton PS, Henderson DW, Kerr KM, Petersen I, Roggli V, Thunnissen E, Tsao M. Diagnosis of Lung Cancer in Small Biopsies and Cytology: Implications of the 2011 International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society Classification. *Arch Pathol Lab Med* 2013;137:668-84.
 - 47) Nakazato Y, Maeshima MA, Ishikawa Y, Yatabe Y, Fukuoka J, Yokose T, Tomita Y, Minami Y, Asamura Y, Tachibana K, Goya T, Noguchi M. Inter observer agreement in the nuclear grading of primary pulmonary adenocarcinoma. *J Thorac Oncol* 2013;8:736-43.
 - 48) Kawamura T, Usui J, Kaseda K, Takeda K, Ebihara I, Ishizu T, Iitsuka T, Sakai K, Takemura K, Kobayashi M, Koyama A, Kanemoto K, Sumazaki R, Uesugi N, Noguchi M, Nagata M, Suka M, Yamagata K. Primary membranoproliferative glomerulonephritis on the decline: decreased rate from the 1970s to the 2000s Japan. *Clin Exp Nephrol* 2013;17:248-54.
 - 49) Usui S, Minami Y, Shiosawa T, Iyama S, Sato Y, Noguchi M. Differences in the prognostic implications of vascular invasion between lung adenocarcinoma and squamous cell carcinoma. *Lung Cancer* 2013;82:407-12.
 - 50) Thunnissen E, Belien JA, Kerr KM, Chung JH, Flieder DB, Noguchi M, Yatabe Y, Hwang DM, Lely RJ, Hartemink KJ, Meijer-Jorna LB, Ysao MS. In compressed lung tissue microscopic sections of adenocarcinoma in situ may mimic papillary adenocarcinoma. *Arch Pathol Lab Med* 2013;137:1792-7.
 - 51) Tachibana K, Minami Y, Shiba-Ishii A, Kano J, Nakazato Y, Sato Y, Goya T, Noguchi M. Abnormality of the hepatocyte growth factor/MET pathway in pulmonary adenocarcinogenesis. *Lung Cancer* 2012;75:181-8.
 - 52) Shiba-Ishii A, Noguchi M. Aberrant stratifin overexpression is regulated by tumor-associated CpG demethylation in lung adenocarcinoma. *Am J Pathol* 2012;180:1653-62.
 - 53) Nakazato Y, Maeshima MA, Ishikawa Y, Yatabe Y, Fukuoka J, Yokose T, Tomita Y, Minami Y, Asamura Y, Tachibana K, Goya T, Noguchi M. Interobserver agreement in the nuclear grading of primary pulmonary adenocarcinoma. *J Thorac Oncol* 2012;8:736-43.
 - 54) Travis WD, Brambilla E, Noguchi M, Nicholson AG, Geisinger KR, Yatabe Y, Beer DG, Powell CA, Riely GJ, Van Schil PE, Garg K, Austin JH, Asamura H, Rusch VW, Hirsch FR, Scagliotti G, Mitsudomi T, Huber RM, Ishikawa Y, Jett J, Sanchez-Cespedes M, Sculier JP, Takahashi T, Tsuboi M, Vansteenkiste J, Wistuba I, Yang PC, Aberle D, Brambilla C, Flieder D, Franklin W, Gazdar A, Gould M, Hasleton P, Henderson D, Johnson B, Johnson D, Kerr K, Kuriyama K, Lee JS, Miller VA, Petersen I, Roggli V, Rosell R, Saijo N, Thunnissen E, Tsao M, Yankelewitz D. International association for the study of lung cancer/american thoracic society/european respiratory society international multidisciplinary classification of lung adenocarcinoma. *J. Thorac Oncol* 2011;6:244-85.
 - 55) Shiba-Ishii A, Kano J, Morishita Y, Sato Y, Minami Y, Noguchi M. High expression of Stratifin is a universal abnormality during the course of malignant progression of early-stage lung adenocarcinoma. *Int J Cancer* 2011;129:2445-53.
 - 56) Behjati R, Kawai K, Inadome Y, Kano J, Akaza H, Noguchi M. APAF-1 is related to an undifferentiated state in the testicular germ cell tumor pathway. *Cancer Science* 2011;102:267-74.
 - 57) Sakashita S, Li D, Nashima N, Minami M, Furuya S, Morishita Y, Tachibana K, Sato Y, Noguchi M. Overexpression of immunoglobulin (CD79a) binding protein1 (IGBP-1) in small lung adenocarcinomas and its clinicopathological significance. *Pathol Int* 2011;61:130-7.
 - 58) Li D, Sakashita S, Morishita Y, Kano J, Shiba-Ishii A, Sato T, Noguchi M. Binding of lactoferrin to IGBP1 triggers apoptosis in a lung adenocarcinoma cell line. *Anticancer Res* 2011;31:529-34.
 - 59) Sugita S, Morishita Y, Kano J, Furuya S, Shiba-Ishii A, Noguchi M. IGBP-1 is expressed specifically in ovarian clear cell adenocarcinoma. *Histopathology* 2011;58:729-38.

- 60) Satomi K, Morishita Y, Sakashita S, Kondou Y, Furuya S, Minami Y, Noguchi M. Specific expression of ZO-1 and N-cadherin in rosette structures of various tumors: possible recapitulation of neural tube formation in embryogenesis and utility as a potentially novel immunohistochemical marker of rosette formation in pulmonary neuroendocrine tumors. *Virchows Arch* 2011;459:399-407.
- 61) Travis WD, Brambilla E, Noguchi M, Nicholson AG, Geisinger K, Yatabe Y, Powell CA, Beer D, Riely G, Garg K, Austin JH, Rusch VW, Hirsch FR, Jett J, Yang PC, Gould M. International association for the study of lung cancer/American Thoracic Society/European Respiratory Society: international multidisciplinary classification of lung adenocarcinoma: executive summary. *Proc Am Thorac Soc* 2011;8:381-5.
- 62) Tanaka H, Kimura T, Kudoh S, Mitsuoka S, Watanabe T, Suzumura T, Tachibana K, Noguchi M, Yano S, Hirata K. Reaction of plasma hepatocyte growth factor levels in non-small cell lung cancer patients treated with EGFR-TKIs. *Int J Cancer* 2011;129:1410-6.
- 63) Nishikii H, Nakamura N, Kondo Y, Okoshi Y, Suzukawa K, Hasegawa Y, Yokoyama Y, Sakata-Yanagimoto M, Enami T, Noguchi M, Chiba S. Treatment outcome of adult burkitt lymphoma in Japanese patients with modified LMB protocol: a signal center retrospective analysis. *J Clin Exp Hematopathol*, 2011;51:109-14.
- 64) Nakazato Y, Minami Y, Kobayashi H, Satomi K, Anami Y, Tsuta K, Tanaka R, Okada M, Goya T, Noguchi M. Nuclear Grading of Primary Pulmonary Adenocarcinomas -Correlation of nuclear size with prognosis-. *Cancer* 2010;116:2011-9.
- 65) Kobayashi H, Minami Y, Anami Y, Kondou Y, Iijima T, Kano J, Morishita Y, Tsuta K, Hayashi S, Noguchi M. Expression of the GA733 gene family and its relationship to prognosis in pulmonary adenocarcinoma. *Virchows Arch* 2010;457:69-76.
- 66) Noguchi M. Stepwise progression of pulmonary adenocarcinoma - clinical and molecular implications. *Cancer Metastasis Rev* 2010;29:15-21.
- 67) Yoshida K, Toki T, Okuno Y, Kanezaki R, Shiraishi Y, Sato-Otsubo A, Sanada M, Park MJ, Terui K, Suzuki H, Kon A, Nagata Y, Sato Y, Wang R, Shiba N, Chiba K, Tanaka H, Hama A, Muramatsu H, Hasegawa D, Nakamura K, Kanegane H, Tsukamoto K, Adachi S, Kawakami K, Kato K, Nishimura R, Izraeli S, Hayashi Y, Miyano S, Kojima S, Ito E, Ogawa S. The landscape of somatic mutations in Down syndrome-related myeloid disorders. *Nat Genet* 2013;45:1293-9.
- 68) Yoshida K, Sanada M, Ogawa S. Deep sequencing in cancer research. *Jpn J Clin Oncol* 2013;43:110-5.
- 69) Shiraishi Y, Sato Y, Chiba K, Okuno Y, Nagata Y, Yoshida K, Shiba N, Hayashi Y, Kume H, Homma Y, Sanada M, Ogawa S, Miyano S. An empirical Bayesian framework for somatic mutation detection from cancer genome sequencing data. *Nucleic Acids Res* 2013;41:e89.
- 70) Sato Y, Yoshizato T, Shiraishi Y, Maekawa S, Okuno Y, Kamura T, Shimamura T, Sato-Otsubo A, Nagae G, Suzuki H, Nagata Y, Yoshida K, Kon A, Suzuki Y, Chiba K, Tanaka H, Niida A, Fujimoto A, Tsunoda T, Morikawa T, Maeda D, Kume H, Sugano S, Fukayama M, Aburatani H, Sanada M, Miyano S, Homma Y, Ogawa S. Integrated molecular analysis of clear-cell renal cell carcinoma. *Nat Genet* 2013;45:860-7.
- 71) Sakaguchi H, Okuno Y, Muramatsu H, Yoshida K, Shiraishi Y, Takahashi M, Kon A, Sanada M, Chiba K, Tanaka H, Makishima H, Wang X, Xu Y, Doisaki S, Hama A, Nakanishi K, Takahashi Y, Yoshida N, Maciejewski JP, Miyano S, Ogawa S, Kojima S. Exome sequencing identifies secondary mutations of SETBP1 and JAK3 in juvenile myelomonocytic leukemia. *Nat Genet* 2013;45:937-41.
- 72) Saida S, Watanabe KI, Sato-Otsubo A, Terui K, Yoshida K, Okuno Y, Toki T, Wang R, Shiraishi Y, Miyano S, Kato I, Morishima T, Fujino H, Umeda K, Hiramatsu H, Adachi S, Ito E, Ogawa S, Ito M, Nakahata T, Heike T. Clonal selection in xenografted TAM recapitulates the evolutionary process of myeloid leukemia in Down syndrome. *Blood* 2013;121:4377-87.
- 73) Nishimura R, Takita J, Sato-Otsubo A, Kato M, Koh K, Hanada R, Tanaka Y, Kato K, Maeda D, Fukayama M, Sanada M, Hayashi Y, Ogawa S. Characterization of genetic lesions in rhabdomyosarcoma using a high-density single nucleotide polymorphism array. *Cancer Sci* 2013;104:856-64.
- 74) Makishima H, Yoshida K, Nguyen N, Przychodzen B, Sanada M, Okuno Y, Ng KP, Gudmundsson KO, Vishwakarma BA, Jerez A, Gomez-Segui I, Takahashi M, Shiraishi Y, Nagata Y, Guinta K, Mori H, Sekeres MA, Chiba K, Tanaka H, Muramatsu H, Sakaguchi H, Paquette RL, McDevitt MA, Kojima S, Sauntharajah Y, Miyano S, Shih LY, Du Y, Ogawa S, Maciejewski JP. Somatic SETBP1 mutations

in myeloid malignancies. *Nat Genet* 2013;45:942-6.

- 75) Kunishima S, Okuno Y, Yoshida K, Shiraishi Y, Sanada M, Muramatsu H, Chiba K, Tanaka H, Miyazaki K, Sakai M, Ohtake M, Kobayashi R, Iguchi A, Niimi G, Otsu M, Takahashi Y, Miyano S, Saito H, Kojima S, Ogawa S. ACTN1 Mutations Cause Congenital Macrothrombocytopenia. *Am J Hum Genet* 2013;92:431-8.
- 76) Kon A, Shih LY, Minamino M, Sanada M, Shiraishi Y, Nagata Y, Yoshida K, Okuno Y, Bando M, Nakato R, Ishikawa S, Sato-Otsubo A, Nagae G, Nishimoto A, Haferlach C, Nowak D, Sato Y, Alpermann T, Nagasaki M, Shimamura T, Tanaka H, Chiba K, Yamamoto R, Yamaguchi T, Otsu M, Obara N, Sakata-Yanagimoto M, Nakamaki T, Ishiyama K, Nolte F, Hofmann WK, Miyawaki S, Chiba S, Mori H, Nakauchi H, Koeffler HP, Aburatani H, Haferlach T, Shirahige K, Miyano S, Ogawa S. Recurrent mutations in multiple components of the cohesin complex in myeloid neoplasms. *Nat Genet* 2013;45:1232-7.
- 77) Okubo J, Takita J, Chen Y, Oki K, Nishimura R, Kato M, Sanada M, Hiwatari M, Hayashi Y, Igarashi T, Ogawa S. Aberrant activation of ALK kinase by a novel truncated form ALK protein in neuroblastoma. *Oncogene* 2012; 31:4667-76.
- 78) Takita J, Chen Y, Okubo J, Sanada M, Adachi M, Ohki K, Nishimura R, Hanada R, Igarashi T, Hayashi Y, Ogawa S. Aberrations of NEGR1 on 1p31 and MYEOV on 11q13 in neuroblastoma. *Cancer Sci* 2011;102:1645-50.
- 79) Yoshida K, Sanada M, Shiraishi Y, Nowak D, Nagata Y, Yamamoto R, Sato Y, Sato-Otsubo A, Kon A, Nagasaki M, Chalkidis G, Suzuki Y, Shiosaka M, Kawahata R, Yamaguchi T, Otsu M, Obara N, Sakata-Yanagimoto M, Ishiyama K, Mori H, Nolte F, Hofmann WK, Miyawaki S, Sugano S, Haferlach C, Koeffler HP, Shih LY, Haferlach T, Chiba S, Nakauchi H, Miyano S, Ogawa S. Frequent pathway mutations of splicing machinery in myelodysplasia. *Nature* 2011;478:64-9.
- 80) Nakahata S, Ichikawa T, Maneesaay P, Saito Y, Nagai K, Tamura T, Manachai N, Yamakawa N, Hamasaki M, Kitabayashi I, Arai Y, Kanai Y, Taki T, Abe T, Kiyonari H, Shimoda K, Ohshima K, Horii A, Shima H, Taniwaki M, Yamaguchi R, Morishita K. Loss of NDRG2 expression activates PI3K-AKT signalling via PTEN phosphorylation in ATLL and other cancers. *Nature Comm* 2014;5:3393.
- 81) Kai H, Akamatsu E, Torii E, Kodama H, Yukizaki C, Akagi I, Ino H, Sakakibara Y, Suiko M, Yamamoto I, Okayama A, Morishita K, Kataoka H, Matsuno K: Identification of a bioactive compound against adult T-cell leukemia from bitter melon seeds. *Plants* 2014;3:18-26.
- 82) Yamamura A, Miura K, Karasawa H, Morishita K, Abe K, Mizuguchi Y, Saiki Y, Fukushima S, Kaneko N, Sase T, Nagase H, Sunamura M, Motoi F, Egawa S, Shibata C, Unno M, Sasaki I, Horii A. Suppressed expression of NDRG2 correlates with poor prognosis in pancreatic cancer. *Biochem Biophys Res Commun* 2013;441:102-7.
- 83) Ikebe E, Kawaguchi A, Tezuka K, Taguchi S, Hirose S, Matsumoto T, Mitsui T, Senba K, Nishizono A, Hori M, Hasegawa H, Yamada Y, Ueno T, Tanaka Y, Sawa H, Hall W, Minami Y, Jeang KT, Ogata M, Morishita K, Hasegawa H, Fujisawa J, Iha H. Oral administration of an HSP90 inhibitor, 17-DMAG, intervenes tumor-cell infiltration into multiple organs and improves survival period for ATL model mice. *Blood Cancer J* 2013;3:e132.
- 84) Sugie S, Mukai S, Tsukino H, Toda Y, Yamauchi T, Nishikata I, Kuroda Y, Morishita K, Kamoto T. Increased plasma caveolin-1 levels are associated with progression of prostate cancer among Japanese men. *Anticancer Res* 2013;33:1893-7.
- 85) Yamasaki M, Mine Y, Nishimura M, Fujita S, Sakakibara Y, Suiko M, Morishita K, Nishiyama K. Genistein induces apoptotic cell death associated with inhibition of the NF- κ B pathway in adult T-cell leukemia cells. *Cell Biol Int* 2013;37:742-7.
- 86) Saito Y, Kaneda K, Suekane A, Ichihara E, Nakahata S, Yamakawa N, Nagai K, Mizuno N, Kogawa K, Miura I, Itoh H, Morishita K. Maintenance of the hematopoietic stem cell pool in bone marrow niches by EVI1-regulated GPR56. *Leukemia* 2013;27:1637-49.
- 87) Yamakawa N, Kaneda K, Saito Y, Ichihara E, Morishita K. The increased expression of integrin α 6 (ITGA6) enhances drug resistance in EVI1^{high} leukemia. *PLoS One* 2012;7:e30706.
- 88) Kondo Y, Nagai K, Nakahata S, Saito Y, Ichikawa T, Suekane A, Taki T, Iwakawa R, Enari M, Taniwaki M, Yokota J, Sakoda S, Morishita K. : Overexpression of the DNA sensor proteins, absent in melanoma 2 and interferon-inducible 16, contributes to tumorigenesis of oral squamous cell carcinoma with p53 inactivation. *Cancer Sci* 2012;103:782-90.
- 89) Nakahata S, Saito Y, Marutsuka K, Hidaka T, Maeda K, Hatakeyama K, Shiraga T, Goto A,

- Takamatsu N, Asada Y, Utsunomiya A, Okayama A, Kubuki Y, Shimoda K, Ukai Y, Kurosawa G, Morishita K. Clinical significance of CADM1/TSLC1/IgSF4 expression in adult T-cell leukemia/lymphoma. *Leukemia* 2012;26:1238-46.
- 90) Nakahata S, Morishita K. CADM1/TSLC1 is a novel cell surface marker for adult T-cell leukemia/lymphoma. *J Clin Exp Hematopathol* 2012;52:17-22.
- 91) Ueno S, Umeki K, Takajo I, Nagatomo Y, Kusumoto N, Umekita K, Morishita K, Okayama A.: Proviral loads of human T-lymphotropic virus Type 1 in asymptomatic carriers with different infection routes. *Int J Cancer* 2012;130:2318-26.
- 92) Takenouchi H, Umeki K, Sasaki D, Yamamoto I, Nomura H, Takajo I, Ueno S, Umekita K, Kamihira S, Morishita K, Okayama A. Defective human T-lymphotropic virus type 1 provirus in asymptomatic carriers. *Int J Cancer* 2011;128:1335-43.
- 93) Saito Y, Nakahata S, Yamakawa N, Kaneda K, Ichihara E, Suekane A, Morishita K. CD52 as a molecular target for immunotherapy to treat acute myeloid leukemia with high EVI1 expression. *Leukemia* 2011;25:921-31.
- 94) Nishikata I, Nakahata S, Saito Y, Kaneda K, Ichihara E, Yamakawa N, Morishita K. Sumoylation of MEL1S at lysine 568 and its interaction with CtBP facilitates its repressor activity and the blockade of G-CSF-induced myeloid differentiation. *Oncogene* 2011;30:4194-4207.
- 95) Ichihara E, Kaneda K, Saito Y, Yamakawa N, Morishita K. Angiopoietin1 contributes to the maintenance of cell quiescence in EVI1^{high} leukemia cells. *Biochem Biophys Res Commun* 2011;416:239-45.
- 96) Shimahara A, Yamakawa N, Nishikata I, Morishita K. Acetylation of lysine 564 adjacent to the C-terminal binding protein-binding motif in EVI1 is crucial for transcriptional activation of GATA2. *J Biol Chem* 2010;285:16967-77.
- 97) Nakahata S, Yamazaki H, Nakauchi H, Morishita K. Downregulation of ZEB1 and overexpression of Smad7 contribute to resistance to TGF- β 1-mediated growth suppression in adult T-cell leukemia/lymphoma. *Oncogene* 2010;29:4157-69.
- 98) Watanabe M, Nakahata S, Hamasaki M, Saito Y, Kawano Y, Hidaka T, Yamashita K., Umeki K, Taki T, Taniwaki M, Okayama A, Morishita K. Downregulation of CDKN1A in adult T-cell leukemia/lymphoma despite overexpression of CDKN1A in human T-lymphotropic virus 1-infected cell lines. *J Virol* 2010;84:6966-77.
- 99) Furuta H, Kondo Y, Nakahata S, Hamasaki M, Sakoda S, Morishita K. NDRG2 is a candidate tumor-suppressor for oral squamous-cell carcinoma. *Biochem Biophys Res Commun* 2010;391:1785-91.
- 100) Yamasaki M, Mukai A, Ohba M, Mine Y, Sakakibara Y, Suiko M, Morishita K, Nishiyama K. : Genistein induced apoptotic cell death in adult T-cell leukemia cells through estrogen receptors. *Biosci Biotechnol Biochem* 2010;74:2113-5.
- 101) Yamamoto I, Takajo I, Umeki K, Morishita K, Hatakeyama K, Kataoka H, Nomura H, Okayama A.: Multiple integrations of human T-lymphotropic virus type 1 proviruses in the engrafted cells from the asymptomatic carriers in NOD/SCID/gammacnull mice. *Intervirology* 2010;53:229-39.
- 102) Hosoda F, Arai Y, Okada N, Shimizu H, Miyamoto M, Kitagawa N, Katai H, Taniguchi H, Yanagihara K, Imoto I, Inazawa J, Ohki M, Shibata T. Integrated Genomic and Functional Analyses Reveal Glyoxalase I as a Novel Metabolic Oncogene in Human Gastric Cancer. *Oncogene* 2013, in press.
- 103) Noro R, Honda K, Tsuta K, Ishii G, Maeshima AM, Miura N, Furuta K, Shibata T, Tsuda H, Ochiai A, Sakuma T, Nishijima N, Gemma A, Asamura H, Nagai K, Yamada T. Distinct outcome of stage I lung adenocarcinoma with ACTN4 cell motility gene amplification. *Ann Oncol* 2013;24:2594-600.
- 104) Yoshida A, Shibata T, Tsuta K, Watanabe S, Tsuda H. Inflammatory myofibroblastic tumor of the lung with a novel isoform of PPF1BP1-ALK fusion gene. *Histopathology* 2013;63:881-3.
- 105) Murakami S, Chisima S, Uemoto H, Sakamoto E, Sato T, Kurabe N, Kawasaki Y, Shibata T, Akiyama H, Tashiro F. The male-specific factor Sry harbors an oncogenic function. *Oncogene* 2013 Jul 29. [Epub ahead of print]
- 106) Nakamura H, Tsuta K, Yoshida A, Shibata T, Wakai S, Asamura H, Furuta K, Tsuda H. Aberrant anaplastic lymphoma kinase expression in high-grade pulmonary neuroendocrine carcinoma. *J Clin Pathol* 2013;66:705-7
- 107) Suzuki T, Shibata T, Takaya K, Shiraishi K, Kohno T, Kunitoh H, Tsuta K, Furuta K, Goto K, Hosoda F, Sakamoto H, Motohashi H, Yamamoto M. Regulatory Nexus of Synthesis and Degradation Deciphers Cellular Nrf2 Expression Levels. *Mol Cell Biol* 2013;33:2402-12.
- 108) Suzuki M, Makinoshima H, Matsumoto S, Suzuki A, Mimaki S, Matsushima K, Yoh K, Goto K, Suzuki

- Y, Ishii G, Ochiai A, Tsuta K, Shibata T, Kohno T, Esumi H, Tsuchihara K. Identification of a lung adenocarcinoma cell line with CCDC6-RET fusion gene and the effect of RET inhibitors in vitro and in vivo. *Cancer Sci* 2013;104:896-903.
- 109) Kitagawa N, Ojima H, Shirakihara T, Shimizu H, Kokubu A, Urushidate T, Totoki Y, Kosuge T, Miyagawa S, Shibata T. Downregulation of the microRNA biogenesis components and its association with poor prognosis in hepatocellular carcinoma. *Cancer Sci* 2013;104:543-51.
- 110) Gailhouse L, Gomez-Santos L, Kitagawa N, Kawaharada K, Thirion M, Kosaka N, Takahashi R, Shibata T, Miyajima A, Ochiya T. MiR-148a plays a pivotal role in the liver by promoting the hepatospecific phenotype and suppressing the invasiveness of transformed cells. *Hepatology* 2013;58:1153-65.
- 111) Arai Y, Totoki Y, Takahashi H, Nakamura H, Hama N, Kohno T, Tsuta K, Yoshida A, Asamura H, Mutoh M, Hosoda F, Tsuda H, Shibata T. Mouse Model for ROS1-Rearranged Lung Cancer. *PLoS One* 2013;8:e56010.
- 112) Wang L, Tsutsumi S, Kawaguchi T, Nagasaki K, Tatsuno K, Yamamoto S, Sang F, Sonoda K, Sugawara M, Hirono S, Yamaue H, Miki Y, Isomura M, Totoki Y, Nagae G, Isagawa T, Hiroki U, Murayama-Hosokawa S, Shibata T, Sakamoto H, Kanai Y, Kaneda A, Noda T, Aburatani H. Whole-exome sequencing of human pancreatic cancers and characterization of genomic instability caused by MLH1 haploinsufficiency and complete deficiency. *Genome Res* 2012;22:208-19.
- 113) Arima Y, Hayashi H, Sasaki M, Hosonaga M, Goto TM, Chiyoda T, Kuninaka S, Shibata T, Ohata H, Nakagama H, Taya Y, Sata H. Induction of ZEB by inactivation of RB is a key determinant of the mesenchymal phenotype of breast cancer. *J Biol Chem* 2012;287:7896-906.
- 114) Shibata T. Cancer genomics and pathology: All Together Now. Review (Solicited). *Patho Int* 2012;62:647-59.
- 115) Fujimoto A, Totoki Y, Abe T, Boroevich KA, Hosoda F, Nguyen HH, Aoki M, Hoshono N, Kubo M, Miya F, Arai Y, Takahashi H, Shirakihara T, Nagasaki M, Shibuya T, Nakao K, Watanabe-Makino K, Tanaka H, Nakamura H, Kusuda J, Ojima H, Shimada K, Okusaka T, Ueno M, Shigekawa Y, Kawakami Y, Arihiro K, Ohdan H, Gotoh K, Ishikawa O, Ariizumi S, Yamamoto M, Yamada T, Chayama K, Kosuge T, Yamae H, Kamatani N, Miyano S, Nakagama H, Nakamura Y, Tsunoda T, Shibata T, Nakagawa H. Whole Genome Sequencing of Liver Cancers Identifies Etiological Influences on Mutation Patterns and Recurrent Mutations in Chromatin Regulators. *Nat Genet* 2012;44:760-4.
- 116) Shibata T, Saito S, Kokubu A, Suzuki T, Yamamoto M, Hirohashi S. Global downstream pathway analysis reveals a dependence of oncogenic NRF2 mutation on the mTOR growth signaling pathway. *Cancer Res* 2010;70:9095-105.
- 117) Shibata T, Kokubu A, Miyamoto M, Sasajima Y, Yamazaki Y. Mutant IDH1 confers an in vivo growth in a melanoma cell line with BRAF mutation. *Am J Pathol* 2011;178:1395-402.
- 118) Shibata T, Kokubu A, Miyamoto M, Hosoda F, Gotoh M, Tsuta K, Asamura H, Matsuno Y, Kondo T, Imoto I, Inazawa J, Hirohashi S. DEK oncoprotein regulates transcriptional modifiers and sustains tumor initiation activity in high-grade neuroendocrine carcinoma of the lung. *Oncogene* 2010;29:4671-81.
- 119) Uno M, Saitoh Y, Mochida K, Tsuruyama E, Kiyono T, Imoto I, Inazawa J, Yuasa Y, Kubota T, Yamaoka S. NF- β Inducing Kinase, a Central Signaling Component of the Non-Canonical Pathway of NF- β , Contributes to Ovarian Cancer Progression. *PLoS One* 2014;9:e88347.
- 120) Takemura K, Kawachi H, Eishi Y, Kitagaki K, Negi M, Kobayashi M, Uchida K, Inoue J, Inazawa J, Kawano T, Board PG. γ -Glutamylcyclotransferase as a novel immunohistochemical biomarker for the malignancy of esophageal squamous tumors. *Hum Pathol* 2014;45:331-41.
- 121) Dobashi Y, Sato E, Oda Y, Inazawa J, Ooi A: Significance of Akt activation and AKT gene increases in soft tissue tumors. *Hum Pathol* 2014;45:127-36.
- 122) Yamamoto S, Inoue J, Kawano T, Kozaki K, Omura K, Inazawa J. The impact of miRNA-based molecular diagnostics and treatment of NRF2-stabilized tumors. *Mol Cancer Res* 2014;12:58-68.
- 123) Low SK, Takahashi A, Ashikawa K, Inazawa J, Miki Y, Kubo M, Nakamura Y, Katagiri T. Genome-wide association study of breast cancer in the Japanese population. *PLoS One* 2013;8:e76463.
- 124) Harazono Y, Muramatsu T, Endo H, Uzawa N, Kawano T, Harada K, Inazawa J, Kozaki K. miR-655 is an EMT-suppressive microRNA targeting ZEB1 and TGFBR2. *PLoS One* 2013;8:e62757.
- 125) Furuta M, Kozaki K, Tanimoto K, Tanaka S, Arai S, Shimamura T, Niida A, Miyano S, Inazawa J. The tumor-suppressive miR-497-195 cluster targets multiple cell-cycle regulators in hepatocellular carcinoma. *PLoS One* 2013;8:e60155.

- 126) Takanashi J, Okamoto N, Yamamoto Y, Hayashi S, Arai H, Takahashi Y, Maruyama K, Mizuno S, Shimakawa S, Ono H, Oyanagi R, Kubo S, Barkovich AJ, Inazawa J. Clinical and radiological features of Japanese patients with a severe phenotype due to CASK mutations. *Am J Med Genet A* 2012;158A:3112-8.
- 127) Gaffney CJ, Oka T, Mazack V, Hilman D, Gat U, Muramatsu T, Inazawa J, Golden A, Carey DJ, Farooq A, Tromp G, Sudol M: Identification, basic characterization and evolutionary analysis of differentially spliced mRNA isoforms of human YAP1 gene. *Gene* 2012; 509:215-22.
- 128) Dobashi Y, Kimura M, Matsubara H, Endo S, Inazawa J, Ooi A: Molecular alterations in AKT and its protein activation in human lung carcinomas. *Hum Pathol* 2012;43:2229-40.
- 129) Miyawaki Y, Kawachi H, Ooi A, Eishi Y, Kawano T, Inazawa J, Imoto I. Genomic copy-number alterations of MYC and FHIT genes are associated with survival in esophageal squamous-cell carcinoma. *Cancer Sci* 2012;103:1558-66.
- 130) Matsumura S, Imoto I, Kozaki K, Matsui T, Muramatsu T, Furuta M, Tanaka S, Sakamoto M, Arai S, Inazawa J. Integrative array-based approach identifies MZB1 as a frequently methylated putative tumor-suppressor in hepatocellular carcinoma. *Clin Cancer Res* 2012;18:3541-51.
- 131) Akamatsu S, Takata R, Haiman CA, Takahashi A, Inoue T, Kubo M, Furihata M, Kamatani N, Inazawa J, Chen GK, Le Marchand L, Kolonel LN, Katoh T, Yamano Y, Yamakado M, Takahashi H, Yamada H, Egawa S, Fujioka T, Henderson BE, Habuchi T, Ogawa O, Nakamura Y, Nakagawa H. Common variants at 11q12, 10q26 and 3p11.2 are associated with prostate cancer susceptibility in Japanese. *Nat Genet* 2012;44:426-9.
- 132) Yamamoto S, Tsuda H, Honda K, Takano M, Tamai S, Imoto I, Inazawa J, Yamada T, Matsubara O: ACTN4 gene amplification and actinin-4 protein overexpression drive tumour development and histological progression in a high-grade subset of ovarian clear-cell adenocarcinomas. *Histopathology* 2012;60:1073-83.
- 133) Ono H, Imoto I, Kozaki K, Tsuda H, Matsui T, Kurasawa Y, Muramatsu T, Sugihara K, Inazawa J. SIX1 promotes epithelial-mesenchymal transition in colorectal cancer through ZEB1 activation. *Oncogene* 2012;31:4923-34.
- 134) Bai H, Inoue J, Kawano T, Inazawa J. A transcriptional variant of the LC3A gene is involved in autophagy and frequently inactivated in human cancers. *Oncogene* 2012;31:4397-408.
- 135) Ooi A, Inokuchi M, Harada S, Inazawa J, Tajiri R, Sawada-Kitamura S, Ikeda H, Kawashima H, Dobashi Y. Gene amplification of ESR1 in breast cancers - Fact or fiction? A fluorescence in situ hybridization and multiplex ligation-dependent probe amplification study. *J Pathol* 2012;227:8-16.
- 136) Kurasawa Y, Kozaki K, Pimkhaokham A, Muramatsu T, Ono H, Ishihara T, Uzawa N, Imoto I, Amagasa T, Inazawa J. Stabilization of phenotypic plasticity through mesenchymal-specific DNA hypermethylation in cancer cells. *Oncogene* 2012;31:1963-74.
- 137) Ishihara T, Inoue J, Kozaki K, Imoto I, Inazawa J. HECT-type ubiquitin ligase ITCH targets lysosomal-associated protein multispinning transmembrane 5 (LAPTM5) and prevents LAPTM5-mediated cell death. *J Biol Chem* 2011;286:44086-94.
- 138) Tsuruta T, Kozaki K, Uesugi A, Furuta M, Hirasawa A, Imoto I, Susumu N, Aoki D, Inazawa J. miR-152 is a tumor suppressor microRNA that is silenced by DNA hypermethylation in endometrial cancer. *Cancer Res* 2011;71:6450-62.
- 139) Uesugi A, Kozaki K, Tsuruta T, Furuta M, Morita K, Imoto I, Omura K, Inazawa J. The tumor suppressive microRNA miR-218 targets the mTOR component Rictor and inhibits AKT phosphorylation in oral cancer. *Cancer Res* 2011;71:5765-78.
- 140) Arai E, Wakai-Ushijima S, Fujimoto H, Hosoda F, Shibata T, Kondo T, Yokoi S, Imoto I, Inazawa J, Hirohashi S, Kanai Y. Genome-wide DNA methylation profiles in renal tumors of various histological subtypes and non-tumorous renal tissues. *Pathobiology* 2011;78:1-9.
- 141) Gotoh M, Arai E, Wakai-Ushijima S, Hiraoka N, Kosuge T, Hosoda F, Shibata T, Kondo T, Yokoi S, Imoto I, Inazawa J, Kanai Y. Diagnosis and prognostication of ductal adenocarcinomas of the pancreas based on genome-wide DNA methylation profiling by bacterial artificial chromosome array-based methylated CpG island amplification. *J Biomed Biotechnol* 2011:780836.
- 142) Nishiyama N, Arai E, Nagashio R, Fujimoto H, Hosoda F, Shibata T, Tsukamoto T, Yokoi S, Imoto I, Inazawa J, Kanai Y. Copy number alterations in urothelial carcinomas: Their clinicopathological significance and correlation with DNA methylation alterations. *Carcinogenesis* 2011;32:462-9.

- 143) Muramatsu T, Imoto I, Matsui T, Kozaki K, Haruki S, Sudol M, Shimada Y, Tsuda H, Kawano T, Inazawa J. YAP is a candidate oncogene for esophageal squamous-cell carcinoma. *Carcinogenesis* 2011;32:389-98.
- 144) Miki D, Kubo M, Takahashi A, Yoon KA, Kim J, Lee GK, Zo JI, Lee JS, Hosono N, Morizono T, Tsunoda T, Kamatani N, Chayama K, Takahashi T, Inazawa J, Nakamura Y, Daigo Y: Variation in TP63 is associated with lung adenocarcinoma susceptibility in Japanese and Korean populations. *Nat Genet*;2-010;42:893-6.
- 145) Takata R, Akamatsu S, Kubo M, Takahashi A, Hosono N, Kawaguchi T, Tsunoda T, Inazawa J, Kamatani N, Ogawa O, Fujioka T, Nakamura Y, Nakagawa H. Genome-wide association study identifies five new susceptibility loci for prostate cancer in the Japanese population. *Nat Genet* 2010;42:751-4.
- 146) Tagi T, Matsui T, Kikuchi S, Hoshi S, Ochiai T, Kokuba Y, Kinoshita-Ida Y, Kisumi-Hayashi F, Morimoto K, Imai T, Imoto I, Inazawa J, Otsuji E. Dermokine as a novel biomarker for early-stage colorectal cancer. *J Gastroenterol* 2010;45:1201-11.
- 147) Shibata T, Kokubu A, Miyamoto M, Hosoda F, Gotoh M, Tsuta K, Asamura H, Matsuno Y, Kondo T, Imoto I, Inazawa J, Hirohashi S. DEK oncoprotein regulates transcriptional modifiers and sustains tumor initiation activity in high-grade neuroendocrine carcinoma of the lung. *Oncogene* 2010;29:4671-81.
- 148) Saitoh Y, Martínez Bruyn VJ, Uota S, Hasegawa A, Yamamoto N, Imoto I, Inazawa J, Yamaoka S. Overexpression of NF-kappaB inducing kinase underlies constitutive NF-kappaB activation in lung cancer cells. *Lung Cancer* 2010;70:263-70.
- 149) Haruki S, Imoto I, Kozaki K, Matsui T, Kawachi H, Komatsu S, Muramatsu T, Shimada Y, Kawano T, Inazawa J. Frequent silencing of protocadherin 17, a candidate tumour suppressor for esophageal squamous-cell carcinoma. *Carcinogenesis* 2010;31:1027-36.
- 150) Prapinjumrune C, Morita KI, Kuribayashi Y, Hanabata Y, Shi Q, Nakajima Y, Inazawa J, Omura K: DNA amplification and expression of FADD in oral squamous cell carcinoma. *J Oral Pathol Med* 2010;39:525-32.
- 151) Tanaka S, Mogushi K, Yasen M, Noguchi N, Kudo A, Nakamura N, Ito K, Miki Y, Inazawa J, Tanaka H, Arii S. Gene-expression phenotypes for vascular invasiveness of hepatocellular carcinomas. *Surgery* 2010;147:405-14.
- 152) Furuta M, Kozaki K, Tanaka S, Arii S, Imoto I, Inazawa J. miR-124 and miR-203 are epigenetically silenced tumor-suppressive microRNAs in hepatocellular carcinoma. *Carcinogenesis* 2010;31:766-76.
- 153) Inoue J, Misawa A, Tanaka Y, Ichinose S, Sugino Y, Hosoi H, Sugimoto T, Imoto I, Inazawa J. Lysosomal-associated protein multispansing transmembrane 5 gene (LAPTM5) is associated with spontaneous regression of neuroblastomas. *PLoS One* 2009;4:e7099.
- 154) Nishiyama N, Arai E, Chihara Y, Fujimoto H, Hosoda F, Shibata T, Kondo T, Tsukamoto T, Yokoi S, Imoto I, Inazawa J, Hirohashi S, Kanai Y. Genome-wide DNA methylation profiles in urothelial carcinomas and urothelia at the precancerous stage. *Cancer Sci* 2010;101:231-40.